- Home
- FRGE vs LYEL Comparison
FRGE vs LYEL Comparison
Compare FRGE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRGE
- LYEL
- Stock Information
- Founded
- FRGE 2014
- LYEL 2018
- Country
- FRGE United States
- LYEL United States
- Employees
- FRGE N/A
- LYEL N/A
- Industry
- FRGE Computer Software: Prepackaged Software
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- FRGE Technology
- LYEL Health Care
- Exchange
- FRGE Nasdaq
- LYEL Nasdaq
- Market Cap
- FRGE 262.8M
- LYEL 253.2M
- IPO Year
- FRGE N/A
- LYEL 2021
- Fundamental
- Price
- FRGE $19.75
- LYEL $16.59
- Analyst Decision
- FRGE Buy
- LYEL Hold
- Analyst Count
- FRGE 5
- LYEL 3
- Target Price
- FRGE $35.50
- LYEL $16.67
- AVG Volume (30 Days)
- FRGE 108.9K
- LYEL 31.2K
- Earning Date
- FRGE 11-04-2025
- LYEL 11-12-2025
- Dividend Yield
- FRGE N/A
- LYEL N/A
- EPS Growth
- FRGE N/A
- LYEL N/A
- EPS
- FRGE N/A
- LYEL N/A
- Revenue
- FRGE $90,840,000.00
- LYEL $60,000.00
- Revenue This Year
- FRGE $32.73
- LYEL N/A
- Revenue Next Year
- FRGE $21.74
- LYEL N/A
- P/E Ratio
- FRGE N/A
- LYEL N/A
- Revenue Growth
- FRGE 14.78
- LYEL 11.11
- 52 Week Low
- FRGE $6.60
- LYEL $7.65
- 52 Week High
- FRGE $24.90
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- FRGE 62.19
- LYEL 52.27
- Support Level
- FRGE $16.16
- LYEL $16.00
- Resistance Level
- FRGE $22.20
- LYEL $18.60
- Average True Range (ATR)
- FRGE 1.31
- LYEL 1.13
- MACD
- FRGE 0.41
- LYEL -0.25
- Stochastic Oscillator
- FRGE 61.72
- LYEL 24.20
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.